Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

97 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01838668

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Fakultni nemocnice u sv. Anny v Brne Brno, Czechia
  • Neurospol, s.r.o. Havířov, Czechia
  • Fakultni nemocnice Hradec Kralove Hradec Králové, Czechia
  • Privatni ordinace - neurologie Hradec Králové, Czechia
View all 54 locations
View Trial Details
Completed

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +11 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Phoenix, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tucson, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fullerton, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
View all 63 locations
View Trial Details
Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

NCT01051349

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Brno, Czechia
  • Research Site Hradec Králové, Czechia
  • Research Site Prague, Czechia
View all 65 locations
View Trial Details
Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Barrow Neurology Clinics Phoenix, Arizona, United States
  • Northwest NeuroSpecialists Tucson, Arizona, United States
  • University of California, Davis Sacramento, California, United States
View all 80 locations
View Trial Details
Completed

Ireland Natalizumab (TYSABRI) Observational Program

NCT01943526

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research site Cork, County Cork, Ireland
  • Research site Dublin, County Dublin, Ireland
  • Research site Galway, County Galway, Ireland
  • Research site Tralee, County Kerry, Ireland
View Trial Details
Completed

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Alabama Neurology Associates Birmingham, Alabama, United States
  • Colorado Springs Neurological Associates Colorado Springs, Colorado, United States
  • Savannah Neurology Specialists Savannah, Georgia, United States
  • Northshore University Evanston, Illinois, United States
View all 23 locations
View Trial Details

Related conditions